Business Context and Reporting Period
This Form 8-K was filed by Nuvilex, Inc. (noted as Pharmacyte Biotech, Inc. in metadata) on May 28, 2014. The report details the entry into a new material definitive agreement for capital raising and the termination of a prior purchase agreement.
Key Financial Metrics and Agreements
- New Capital Raising Facility: Entered into an "at-the-market" offering agreement with Chardan Capital Markets, LLC to sell up to $50,000,000 of common stock.
- Compensation Structure:
- 3% cash fee on gross proceeds from "at-the-market" sales.
- 7% cash fee plus 5% warrants on distinct block sales.
- Expense reimbursement capped at $15,000.
- Terminated Agreement: Terminated a prior purchase agreement with Lincoln Park Capital Fund, LLC, which originally allowed for the sale of up to $25,000,000 in stock (with $2,000,000 previously purchased).
- Share Issuance: Issued 1,062,500 shares of common stock to Lincoln Park as consideration for consenting to the new Chardan Agreement.
Material Changes Versus Prior Period
The primary material change is the replacement of the Lincoln Park Capital Fund purchase agreement with the Chardan Capital Markets engagement. While the Lincoln Park agreement is terminated, specific obligations survive, including the registration rights for Lincoln Park's existing 14,125,000 shares and indemnification provisions. The Variable Rate Covenants will terminate upon the earlier of one year from the registration effectiveness date or the full sale of Lincoln Park's shares.
Guidance, Outlook, and Risks
- Outlook: The company has secured a mechanism to raise up to $50 million depending on market conditions, providing flexibility for future capital needs.
- Conditions: The Chardan Agreement is contingent on Lincoln Park's consent, which was granted provided the new agreement does not conflict with Lincoln Park's ability to sell its registered shares.
- Risks: The filing does not provide specific financial guidance, revenue projections, or liquidity metrics. The success of the capital raise is subject to market conditions and the discretion of the Company.
Investor Verification Checklist
- Verify the current share count and the impact of the 1,062,500 shares issued to Lincoln Park on dilution.
- Confirm the status of the registration statement for Lincoln Park's 14,125,000 shares to understand the timeline for the termination of Variable Rate Covenants.
- Review the press release (Exhibit 99.1) for any additional details on the company's immediate cash position or use of proceeds.
- Note that the filing text does not provide clear values for current revenue, profit, cash flow, or total debt.